Genscript Biotech 将来の成長

Future 基準チェック /36

Genscript Biotech利益と収益がそれぞれ年間91.9%と2.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に3.9% 91%なると予測されています。

主要情報

91.9%

収益成長率

91.04%

EPS成長率

Life Sciences 収益成長	30.0%
収益成長率	2.8%
将来の株主資本利益率	3.90%
アナリストカバレッジ	Good
最終更新日	25 Aug 2025

今後の成長に関する最新情報

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Recent updates

We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings

Sep 18

Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet

Sep 08

Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues

Jul 29

At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?

Jul 24

Global Demand Rebound Will Drive Life Sciences And CDMO Expansion

Jul 17 Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.

Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?

May 14

Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Apr 07

Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump

Feb 12

Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 20

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Nov 19

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Oct 01

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Sep 16

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Aug 02

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Jun 05

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

May 10

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 13

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Mar 13

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 26

Is Genscript Biotech (HKG:1548) A Risky Investment?

Nov 21

Is Genscript Biotech (HKG:1548) A Risky Investment?

Aug 22

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Apr 04

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 02

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Feb 07

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Dec 14

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 09

Is Genscript Biotech (HKG:1548) Using Debt Sensibly?

Oct 22

Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?

Apr 03

業績と収益の成長予測

SEHK:1548 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	921	295	80	239	10
12/31/2026	809	99	39	258	10
12/31/2025	949	66	89	222	8
6/30/2025	828	5	126	228	N/A
3/31/2025	711	-31	2	152	N/A
12/31/2024	594	-67	-121	76	N/A
6/30/2024	454	419	-276	-20	N/A
3/31/2024	507	421	-410	-153	N/A
12/31/2023	560	423	-543	-287	N/A
9/30/2023	773	-140	-506	-266	N/A
6/30/2023	707	-185	-523	-245	N/A
3/31/2023	667	-206	-431	-183	N/A
12/31/2022	626	-227	-339	-120	N/A
9/30/2022	598	-315	-321	-142	N/A
6/30/2022	570	-403	-304	-163	N/A
3/31/2022	530	-381	-289	-150	N/A
12/31/2021	490	-359	-274	-137	N/A
9/30/2021	483	-265	-265	-127	N/A
6/30/2021	454	-183	-256	-118	N/A
3/31/2021	422	-194	-268	-134	N/A
12/31/2020	391	-205	-279	-151	N/A
9/30/2020	354	-194	-171	-48	N/A
6/30/2020	318	-183	-64	54	N/A
3/31/2020	296	-140	-103	12	N/A
12/31/2019	273	-97	-142	-30	N/A
9/30/2019	257	-59	-207	-116	N/A
6/30/2019	241	-22	-272	-202	N/A
3/31/2019	236	0	N/A	53	N/A
12/31/2018	231	21	N/A	308	N/A
9/30/2018	216	24	N/A	338	N/A
6/30/2018	201	27	N/A	369	N/A
3/31/2018	177	26	N/A	195	N/A
12/31/2017	153	26	N/A	21	N/A
9/30/2017	139	27	N/A	24	N/A
6/30/2017	125	28	N/A	27	N/A
3/31/2017	120	27	N/A	30	N/A
12/31/2016	115	26	N/A	33	N/A
9/30/2016	107	26	N/A	29	N/A
6/30/2016	99	25	N/A	25	N/A
3/31/2016	93	21	N/A	22	N/A
12/31/2015	87	18	N/A	20	N/A
9/30/2015	82	13	N/A	18	N/A
6/30/2015	78	8	N/A	16	N/A
3/31/2015	74	7	N/A	14	N/A
12/31/2014	70	6	N/A	12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 1548の予測収益成長率 (年間91.9% ) は貯蓄率 ( 2.7% ) を上回っています。

収益対市場: 1548の収益 ( 91.9% ) はHong Kong市場 ( 13% ) よりも速いペースで成長すると予測されています。

高成長収益: 1548の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 1548の収益 ( 2.8% ) Hong Kong市場 ( 8.8% ) よりも低い成長が予測されています。

高い収益成長: 1548の収益 ( 2.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 1548の自己資本利益率は、3年後には低くなると予測されています ( 3.9 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/10/09 00:08
終値	2025/10/09 00:00
収益	2025/06/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Genscript Biotech Corporation 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。15

アナリスト	機関
Jin Zhang	China International Capital Corporation Limited
Shitong Han	Citic Securities Co., Ltd.
Zhu Chen	Citic Securities Co., Ltd.

Genscript Biotech 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 46%

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Consensus revenue estimates fall by 19%

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Consensus forecasts updated

Recent updates

We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings

New minor risk - Profit margin trend

Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet

CEO & COO exercised options and sold HK$2.0m worth of stock

First half 2025 earnings released: US$0.012 loss per share (vs US$0.083 loss in 1H 2024)

GenScript Biotech Corporation Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

Genscript Biotech Corporation to Report First Half, 2025 Results on Aug 16, 2025

Now 22% undervalued

Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues

At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?

Global Demand Rebound Will Drive Life Sciences And CDMO Expansion

Executive Chairman exercised options and sold HK$11m worth of stock

Executive Chairman exercised options and sold HK$4.9m worth of stock

Now 22% undervalued

CEO & COO exercised options and sold HK$4.1m worth of stock

Genscript Biotech Corporation Announces New 5-Year Survey Data for Carvykti in Cartitude-1 Study for Multiple Myeloma at 2025

Genscript Biotech Corporation Announces Board and Committee Changes, Effective 29 May 2025

Co-Founder exercised options and sold HK$22m worth of stock

Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?

Co-Founder exercised options and sold HK$39m worth of stock

Co-Founder exercised options and sold HK$52m worth of stock

Board Member recently sold HK$481k worth of stock

Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation, Annual General Meeting, May 29, 2025

Genscript Biotech Corporation to Report Fiscal Year 2024 Results on Mar 11, 2025

Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump

Genscript Biotech Corporation Announces Establishment of A Sub-Committee of the Risk Management and ESG Committee

Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate

Executive Chairman exercised options and sold HK$5.5m worth of stock

Executive Chairman recently sold HK$396k worth of stock

Co-Founder exercised options and sold HK$53m worth of stock

Co-Founder exercised options and sold HK$43m worth of stock

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Now 22% overvalued after recent price rise

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Genscript Biotech Corporation Announces Board Appointments

Consensus EPS estimates fall by 46%

First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?